Sarcoma News

FDA granted full approval to pembrolizumab for treatment of certain adults and children with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors as determined through an FDA-approved test.

Intermittent milademetan appeared effective and mitigated dose-limiting hematologic adverse events among patients with advanced solid tumors and lymphomas, according to study results published in Journal of Clinical Oncology.

SEATTLE — Because people with HIV who are being successfully treated with ART have a close to normal life expectancy, most deaths among those with HIV are now caused by unrelated comorbidities, a study found.

SEATTLE — People in East Africa with HIV-related Kaposi’s sarcoma often have advanced disease and a poor survival outlook — and the situation has not improved in the last 5 years, a study found.

Childhood, adolescent and young adult survivors of bone and soft tissue sarcomas had an increased risk for second malignant neoplasms, according to study results in Cancer.

It’s not often that a 2 a.m. phone call marks the highlight of someone’s career.

A restrictive opioid prescription protocol of 3 days or less after hospital discharge appeared feasible among a cohort of patients who underwent surgery at a large cancer center, according to study results published in JAMA Oncology.

Joyce Ohm, PhD, has been named chair of cancer genetics and genomics at Roswell Park Comprehensive Cancer Center.

The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic alveolar soft part sarcoma.

According to published results, use of a 0.05% chlorhexidine gluconate solution may serve as a chemical adjuvant to intralesional curettage for patients with chondrosarcomas and giant cell tumors.